Results from the Early Treatment for Retinopathy of Prematurity Clinical Trial
The ETROP study tested the hypothesis that earlier treatment of high-risk infants would result in a better visual outcome than conventional treatment at threshold. 5, 6 Earlier treatment was defined as ablation of the avascular retina in high-risk, pre-threshold eyes. High risk was determined using a computer program (RM-ROP2) based on data from the Cryotherapy for ROP (CRYO-ROP) natural history cohort. Pre-threshold eyes included those with any ROP in zone I, those with plus disease but without stage 3 or with insufficient stage 3 for threshold, and eyes with stage 3 but without plus disease.
Of 828 infants identified at pre-threshold, 499 were determined to be high risk. Of these, 401 were randomized-317 were bilateral cases and 84 were asymmetric cases in which the one eye was randomized to treatment or control. Treatment was ablation of the peripheral avascular retina at highrisk pre-threshold, and those in the control group were observed and treated only if threshold was reached. even for experts, the assessment of plus disease is often an educated guess. The CRYO-ROP study group wrote that there is a need for a practical way to quantify plus disease that would permit further exploration of the effect of plus disease on ROP outcome. 10 We have developed a computer program, called 'ROPtool,' that automatically traces retinal blood vessels and measures their tortuosity. 11 It expresses tortuosity as 'tortuosity index,' and a tortuosity index greater than 10 has more tortuosity than the average of all vessels in the standard photograph of plus disease. In a pilot study of ROPtool, we found that inter-user agreement was at least as good as inter-examiner judgment. This pilot study also allowed us to determine appropriate numeric thresholds for plus tortuosity and pre-plus tortuosity using the consensus of two examiners as the reference standard. ROPtool had a sensitivity of 100% (11/11) and a specificity of 78% (7/9) in the detection of tortuosity sufficient for plus disease, and its overall accuracy was 90% (18/20).
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This pilot study showed that ROPtool is a promising technology for reducing the subjectivity of plus disease assessment. The computer program needs to be validated with more images and its measurement of dilation needs to be improved. It is also unknown how well ROPtool will work with video images. If it will accurately measure vascular abnormality in videos obtained during routine indirect ophthalmoscopy, this technology could easily be applied at the bedside. In the future, ROPtool may be useful to augment expert judgment of plus disease as part of medical consultations. Several studies have shown that remote screening for ROP is feasible. [12] [13] [14] The precise degree of vascular dilation and tortuosity will be useful for studying the evolution and mechanism of plus disease. It could also correlate with prognosis, affect treatment decisions, and influence follow-up intervals.
Conclusions
In conclusion, many advances have been made in ROP diagnosis and treatment over the past decade; however, many challenges remain. Despite promising results from the ETROP study, severe cases of ROP that are relatively unresponsive to laser treatment still exist. Could there be a role for anti-vascular endothelial growth factor (VEGF) agents in the management of these difficult cases? 15 It is also unknown whether curtailing supplemental oxygen will have a beneficial effect on ROP without causing other morbidities. 16, 17 Finally, other methods for preventing ROP will be studied, such as the administration of inositol. 18 ■
